Key Points Intuitive Surgical handily beat Q3 revenue and earnings estimates. The robotic surgical systems leader also increased its outlook for da Vinci procedure volume. 10 stocks we like better than Intuitive Surgical › Shares of Intuitive Surgical (NASDAQ: ISRG) were skyrocketing 16% higher as of 11 a.m. ET on Wednesday. The big jump came after the robotic surgical systems pioneer announced its third-quarter results following the market close on Tuesday. Intuitive Surgical reported Q3 revenue ...

Core Insights - Intuitive Surgical's shares have decreased by approximately 26% from their peak earlier this year, yet long-term shareholders have seen a remarkable increase of 5,490% over the past 20 years [1] Competitive Landscape - Intuitive Surgical faces competitive pressure from Medtronic, which has introduced the Hugo RAS system that showed successful results in a urologic procedure study [2] - Medtronic's Hugo RAS system received its first marketing approval from European regulators in 2021, and an application for U.S. marketing is expected to be submitted to the FDA, potentially allowing sales to begin in early 2026 [4] Operational Performance - In 2024, da Vinci systems conducted 2.68 million procedures, and the company expanded its da Vinci machine installations by 1,790 to a total of 11,040 globally [5] - Hospitals investing in da Vinci systems also commit significant resources to training surgical teams, creating high switching costs that hinder competitors like Medtronic from capturing market share [5] Financial Metrics - Despite the recent decline, Intuitive Surgical's shares are trading at over 55 times earnings estimates, indicating a high valuation [6] - The company anticipates a procedure volume increase of 15.5% to 17% for the year, suggesting strong growth potential [6]

Core Viewpoint - The Nasdaq Composite index has experienced significant volatility, recently entering a bear market but showing signs of recovery, presenting potential buying opportunities for long-term investors in select stocks [2][3]. Group 1: Alphabet - Alphabet's share price is down approximately 25% from its all-time high earlier this year, creating a favorable buying opportunity for long-term investors [4]. - The company has a price-to-earnings-to-growth (PEG) ratio of 1.04, indicating reasonable valuation based on five-year earnings growth projections [4]. - Google Cloud is the fastest-growing major cloud services provider, and the rollout of its Gemini large language model has positioned it competitively against OpenAI's ChatGPT [5]. - Google Search has integrated generative AI features, leading to increased search usage and user satisfaction, which is expected to drive robust growth [6]. - Future revenue growth is anticipated from Alphabet's Waymo self-driving car technology unit [6]. Group 2: Intuitive Surgical - Intuitive Surgical's share price is down about 6% from the beginning of the year, but it remains a strong long-term investment [7]. - The company has over 10,670 robotic surgical systems installed globally, with nearly 2.7 million procedures performed last year, showcasing its market leadership [8]. - A significant 84% of Intuitive Surgical's total revenue in 2024 is expected to come from recurring sources, up from 71% in 2017, indicating strong cash flow [9]. - The company estimates that there are 8 million procedures annually that it can target, which is nearly three times its current procedure volume, with additional potential in 22 million procedures under development [10]. Group 3: Vertex Pharmaceuticals - Vertex Pharmaceuticals has achieved a 17.5% gain so far in 2025, indicating strong momentum [12]. - The company holds a virtual monopoly in treating cystic fibrosis, bolstered by the FDA approval of Alyftrek, which offers more convenient dosing and potentially higher profitability [13]. - Vertex's new drug Journavx, approved in January, is the first new class of pain medication in over 20 years, expected to be commercially successful due to its non-addictive properties [14]. - The company is also advancing the rollout of Casgevy, a gene-editing therapy for sickle cell disease, and has a promising pipeline with four late-stage programs, including one aimed at curing severe type 1 diabetes [15].